

**Dr. Balázs Balogh**  
**LIST OF PUBLICATIONS**  
**2003-2017**

1. Anwair M.A.S., Károlyházy L., Szabó D., **Balogh B.**, Kövesdi I., Harmat V., Krenyác J., Gellért Á., Takács-Novák K., Mátyus P.:  
Lipophilicity of aminopyridazinone regioisomers.  
*J. Agric. Food Chem.*, **51**, 5262-5270 (2003). DOI:10.1021/jf0343938  
IF 2.102
2. Keglevich Gy., Kégl T., Chuluunbaatar T., Dajka B., Mátyus P., **Balogh B.**, Kollár L.:  
Hydroformylation of styrene in the presence of rhodium-2,4,6-trialkylphenyl-phosphole  
in situ catalytic systems.  
*J. Mol. Catal. A: Chem.*, **200**, 131-136 (2003). DOI:10.1016/S1381-1169(03)00046-3  
IF 2.264
3. Bágyi I., **Balogh B.**, Czajlik A., Éliás O., Gáspári Z., Gergely V., Hudáky I., Hudáky P.,  
Kalászi A., Károlyházy L., Keserű K., Kiss R., Krajsovsky G., Láng B., Nagy T.,  
Rác Á., Szentesi A., Tábi T., Tapolcsányi P., Vaik J., Koo J.C.P., Chass G.A.,  
Farkas Ö., Perczel A., Mátyus P.:  
Generation and analysis of the conformational potential energy surfaces of  
*N*-acetyl-*N*-methyl-L-alanine-*N*'-methylamide. An exploratory ab initio study.  
*J. Mol. Struct. (Theochem)*, **625**, 121-136 (2003). DOI:10.1016/S0166-1280(03)00009-5  
IF 1.027
4. Borosy A.P., **Balogh B.**, Mátyus P.:  
Alignment-free descriptors for quantitative structure-rate constant relationships of  
[4+2]cycloadditions.  
*J. Mol. Struct. (Theochem)*, **729**, 169-176 (2005). DOI:10.1016/j.theochem.2005.01.054  
IF 1.045
5. **Balogh B.**, Hetényi Cs., Keserű Gy.M., Mátyus P.:  
Structure-based calculation of binding affinities of  $\alpha_{2A}$ -adrenoceptor agonists.  
*ChemMedChem*, **2**, 801-805 (2007). DOI:10.1002/cmdc.200600251  
IF 2.825
6. Jójárt B., **Balogh B.**, Márki A.:  
Modeling the human oxytocin receptor for drug discovery efforts.  
*Expert Opin. Drug Discovery*, **2**, 1579-1590 (2007). DOI:10.1517/17460441.2.12.1579  
IF 1.354 (2009)
7. **Balogh B.**, Jójárt B., Wágner Zs., Kovács P., Gyires K., Zádori Z., Falkay Gy.,  
Márki Á., Viskolcz B., Mátyus P.:  
3D QSAR models for  $\alpha_{2a}$ -adrenoceptor agonists.  
*Neurochem. Int.*, **51**, 268-276 (2007). DOI:10.1016/j.neuint.2007.05.021  
IF 2.975

8. Daruházi Á.E., Szente L., **Balogh B.**, Mátyus P., Béni Sz., Takács M., Gergely A., Horváth P., Szőke É., Lemberkovichs É.:  
Utility of cyclodextrins in the formulation of genistein Part 1. Preparation and physicochemical properties of genistein complexes with native cyclodextrins.  
*J. Pharm. Biomed. Anal.* **48**, 636-640 (2008). DOI:10.1016/j.jpba.2008.06.007  
IF 2.629
9. **Balogh B.**, Szilágyi A., Gyires K., Bylund D.B., Mátyus P.:  
Molecular modelling of subtypes ( $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ ) of  $\alpha_2$  adrenoceptors: A comparative study.  
*Neurochem. Int.*, **55**, 355-361(2009). DOI:10.1016/j.neuint.2009.05.004  
IF 3.541
10. Mercader J., Iffiú-Soltész Zs., Brenachot X., Földi Á., Dunkel P., **Balogh B.**, Attané C., Valet P., Mátyus P., Carpéné C.:  
SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders.  
*Future Med. Chem.*, **2**, 1735-1749 (2010). DOI:10.4155/fmc.10.260  
IF 1.424
11. Dunkel P., **Balogh B.**, Meleddu R., Maccioni E., Gyires K., Mátyus P.:  
Semicarbazide sensitive amine oxidase/vascular adhesion protein-1: A patent survey.  
*Expert Opin. Ther. Patents*, **21**, 1453-1471 (2011). DOI:10.1517/13543776.2011.594040  
IF 3.571
12. Arany Á., Bolgár B., **Balogh B.**, Antal P., Mátyus P.:  
Multi-aspect candidates for repositioning: Data fusion methods using heterogeneous information sources.  
*Curr. Med. Chem.*, **20**, 95-107 (2013). DOI:10.2174/0929867311302010010  
IF 3.715
13. Bolgár B., Arany Á., Temesi G., **Balogh B.**, Antal P., Mátyus P.:  
Drug repositioning for treatment of movement disorders: From serendipity to rational discovery strategies.  
*Curr. Top. Med. Chem.*, **13**, 2337-2367 (2013). DOI:10.2174/15680266113136660164  
IF 3.453
14. Tóth L., Fu Y., Zhang H.Y., Mándi A., Kövér K.E., Illyés T.Z., Kiss-Szikszai A., **Balogh B.**, Kurtán T., Antus S., Mátyus P.:  
Preparation of neuroprotective condensed 1,4-benzoxazepines by regio- and diastereoselective domino knoevenagel-[1,5]-hydride shift-cyclization reaction.  
*Beilstein J. Org. Chem.*, **10**, 2594-2602 (2014). DOI:10.3762/bjoc.10.272  
IF 2.757

16. Parrino B., Carbone A., Ciancimino C., Spano V., Montalbano A., Barraja P., Cirrincione G., Diana P., Sissi C., Palumbo M., Pinato O., Pennati M., Beretta G., Folini M., Mátyus P., **Balogh B.**, Zaffaroni N.:  
Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: In vitro antiproliferative activity and molecular mechanism(s) of action.  
*Eur. J. Med. Chem.*, **94**, 149-162 (2015). DOI:10.1016/j.ejmech.2015.03.005  
IF 3.902
  
17. Huleatt P.B., Khoo M.L., Chua Y.Y., Tan T.W., Liew R.S., **Balogh B.**, Deme R., Gölöncsér F., Magyar K., Sheela D.P., Ho H.K., Sperlágh B., Mátyus P., Chai C.L.L.:  
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.  
*J. Med. Chem.*, **58**, 1400-1419 (2015). DOI:10.1021/jm501722s  
IF 5.589
  
18. **Balogh B.**, Pázmány T., Mátyus P.:  
Analysis of Edg-Like LPA receptor-ligand interactions.  
*Curr. Pharm. Des.* **21**, 3533-3547 (2015). DOI:10.2174/1381612821666150216120500  
IF 3.052
  
19. Carpéné C., Hasnaoui M., **Balogh B.**, Mátyus P., Fernandez-Quintela A., Rodriguez V., Portillo M. P., Mercader J.:  
Dietary phenolic compounds interfere with the fate of hydrogen peroxide in human adipose tissue but do not directly inhibit primary amine oxidase activity.  
*Oxid. Med. Cell. Longevity* ID 2427618 (2016). DOI:10.1155/2016/2427618  
IF 4.492
  
20. Les Parellada F., Deleruyelle S., Cassagnes L. E., Nepveu F., Boutin J. A., **Balogh B.**, Arbones-Mainar J. M., Biron S., Marceau P., Richard D., Nepveu F., Mauriège P., Carpéné C.:  
Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.  
*Chem.-Biol. Interact.* **258**, 115-125, (2016). DOI:10.1016/j.cbi.2016.07.014  
IF 2.618
  
21. **Balogh B.**, Carbone A., Spano V., Montalbano, A., Barraja P., Cascioferro S., Diana P., Parrino B.:  
Investigation of isoindolo[2,1-a]quinoxaline-6-imines as topoisomerase I inhibitors with molecular modeling methods.  
*Curr. Comp.-Aided Drug Des.* **13**, 208-221 (2017).  
DOI:10.2174/1573409913666170124100334  
IF 0.77

## PATENT

Mátyus P., Németh J., Magyar K., Somogyi A., Dunkel P., Somfai G.M., **Balogh B.**, Túrós Gy.:  
Use of dihydralazine for the treatment of diseases related to elevated semicarbazide-sensitive amine oxidase (SSAO) activity.  
PCT Int. Appl. (2010), [WO 2010015870 A1 20100211](#)